Sign Up to like & get recommendations! 0
Published in 2020 at "ESC Heart Failure"
DOI: 10.1002/ehf2.12832
Abstract: Hypertension is a major contributor to cardiac diastolic dysfunction. Different therapeutics strategies have been proposed to control blood pressure (BP), but their independent impact on cardiac function remains undetermined. In patients with resistant hypertension, we… read more here.
Sign Up to like & get recommendations! 1
Published in 2020 at "European Journal of Heart Failure"
DOI: 10.1002/ejhf.1860
Abstract: The AMBER trial demonstrated that concomitant use of patiromer enabled the more persistent use of spironolactone by reducing the risk of hyperkalaemia in patients with resistant hypertension and advanced chronic kidney disease. We report herein… read more here.
Sign Up to like & get recommendations! 1
Published in 2021 at "Sleep and Breathing"
DOI: 10.1007/s11325-021-02490-1
Abstract: Epidemiological studies have shown an increased prevalence and incidence of hypertension as well as a higher incidence of stroke among patients suffering from RLS. The objective of this study was to estimate the prevalence of… read more here.
Sign Up to like & get recommendations! 0
Published in 2017 at "International journal of cardiology"
DOI: 10.1016/j.ijcard.2016.12.158
Abstract: OBJECTIVE The efficacy of add-on use of spironolactone in patients with resistant hypertension has been investigated in several small studies. We performed this meta-analysis evaluating the efficacy of add-on use of spironolactone in these patients.… read more here.
Sign Up to like & get recommendations! 0
Published in 2017 at "Journal of the American College of Cardiology"
DOI: 10.1016/s0735-1097(17)35189-6
Abstract: Aim: The purpose of the study was to investigate the incidence of subclinical atherosclerosis by coronary artery calcium(CAC) score and atherosclerotic cardiovascular disease(ASCVD) risk score in patients with resistant hypertension. Methods: For 8823 subjects taking… read more here.
Sign Up to like & get recommendations! 0
Published in 2017 at "Scientific Reports"
DOI: 10.1038/s41598-017-18671-6
Abstract: The aim of the present study is to systematically evaluate the impact of RDN on cardiac structure and function in patients with resistant hypertension (RH) or diastolic dysfunction. We retrieved Pubmed, Embase and Cocharane Library… read more here.
Sign Up to like & get recommendations! 1
Published in 2022 at "Expert Review of Hematology"
DOI: 10.1080/17474086.2022.2077187
Abstract: ABSTRACT Introduction Chronic myeloid leukemia is now a highly treatable leukemia due to the availability of multiple tyrosine kinase inhibitors (TKIs) inhibiting the BCR-ABL1 oncogene. Some patients with CML can display resistance or intolerance to… read more here.
Sign Up to like & get recommendations! 0
Published in 2019 at "European heart journal cardiovascular Imaging"
DOI: 10.1093/ehjci/jez025
Abstract: AIMS Impaired myocardial perfusion reserve (MPR) may occur earlier than coronary atherosclerosis and it may be an early manifestation of developing coronary artery disease (CAD) in patients with resistant hypertension (RH). We evaluated the relationship… read more here.
Sign Up to like & get recommendations! 0
Published in 2019 at "European Heart Journal"
DOI: 10.1093/eurheartj/ehz745.0955
Abstract: Diabetic patients with resistant hypertension (RHT) are characterized by accelerated annual decline in estimated glomerular filtration rate (eGFR) (from 10 to 14 mL/min/1,73m2). The distal renal denervation (RD) can preserve renal function within first year… read more here.
Sign Up to like & get recommendations! 0
Published in 2018 at "Journal of Hypertension"
DOI: 10.1097/01.hjh.0000539027.16061.59
Abstract: Objective: The aim of this study was to evaluate of state the heart after distal renal denervation (DRD) in segmental branches of renal artery versus conventional main trunk therapy: 12 month study in patients with… read more here.
Sign Up to like & get recommendations! 0
Published in 2019 at "Journal of Hypertension"
DOI: 10.1097/01.hjh.0000570384.94384.e7
Abstract: Objective:Endovascular baroreflex amplification (EVBA) is a novel device-based therapy that has been shown to lower blood pressure (BP) in patients with resistant hypertension (RHTN) in an uncontrolled first-in-human study. It is postulated that EVBA lowers… read more here.